PTC Therapeutics (PTCT) Posts Q4 Loss of 84c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
PTC Therapeutics (PTCT) Target Lifted to $81 at Wedbush
March 2, 2015 12:52 PM ESTWedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on PTC Therapeutics (NASDAQ: PTCT) to $81.00 (from $68.00), noting the Translarna launch is off to a good start.
Behanna commented, "A combination of commercial launch in Germany and reimbursed expanded access... More
PTC Therapeutics (PTCT) PT Raised on BofA/Merrill Lynch on ex-US Translarna Sales
March 2, 2015 8:07 AM ESTBofA/Merrill Lynch analyst Tazeen Ahmad reiterated a Buy rating and boosted its price target on PTC Therapeutics (NASDAQ: PTCT) to $87.00 (from $60.00) following Q4 results and ex-US Translarna sales.
Ahmad notes that on the call PTC reported early ex-US launch metrics for its... More
